spliceswitch antigens oligonucleotid emerge treatment neuromuscular disease sever sso current undergo clinic trial duchess muscular dystrophy dmy spinal atrophy sma howe develop system deli therapeutic hamper poor tissue center cellular uptake include cross bloodbrain barrier bbb reach target central nervous system cn applied investing bail various bbbcross peptide delivery phosphorodiamid morpholino oligonucleotid pm target survive motor neuron smn exon include identify branch derive wellknown apo peptide concur capable follow system administer lead increase level fulllength transcript treatment newborn mouse peptidepmo ppo result signifies average lifespan gain weight muscle strength right reflex adult newly also small increase level premesseng rna mra periphery tissue work provide proof principal select new paradigm enhance active sso use peptides platform potent extend neurodegen 